alsterpaullone and Myotonic-Dystrophy

Glycogen synthase kinase 3 β (GSK-3β) is a central target in several unmet diseases. To increase the specificity of GSK-3β inhibitors in chronic treatments, we developed small molecules allowing subtle modulation of GSK-3β activity. Design synthesis, structure-activity relationships, and binding mode of quinoline-3-carbohydrazide derivatives as allosteric modulators of GSK-3β are presented here. Furthermore, we show how allosteric binders may overcome the β-catenin side effects associated with strong GSK-3β inhibition. The therapeutic potential of some of these modulators has been tested in human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients. We found that compound 53 improves delayed myogenesis in CDM1 myoblasts, while compounds 1 and 53 have neuroprotective properties in SMA-derived cells. These findings suggest that the allosteric modulators of GSK-3β may be used for future development of drugs for DM1, SMA, and other chronic diseases where GSK-3β inhibition exhibits therapeutic effects.

Topics: Allosteric Site; beta Catenin; Chemistry Techniques, Synthetic; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Induced Pluripotent Stem Cells; Molecular Docking Simulation; Molecular Dynamics Simulation; Muscular Atrophy, Spinal; Myoblasts, Skeletal; Myotonic Dystrophy; Quinolines; Structure-Activity Relationship